Cardiovascular Diseases and Panax ginseng: A Review on Molecular Mechanisms and Medical Applications

  • Kim, Jong-Hoon (Department of Veterinary Physiology, College of Veterinary Medicine, Biosafety Research Institute, Chonbuk National University)
  • Received : 2011.10.14
  • Accepted : 2011.12.14
  • Published : 2012.01.11


Ginseng is one of the most widely used herbal medicines and is reported to have a wide range of therapeutic and pharmacological applications. Ginseng may also be potentially valuable in treating cardiovascular diseases. Research concerning cardiovascular disease is focusing on purified individual ginsenoside constituents of ginseng to reveal specific mechanisms instead of using whole ginseng extracts. The most commonly studied ginsenosides are $Rb_1$, $Rg_1$, $Rg_3$, $Rh_1$, Re, and Rd. The molecular mechanisms and medical applications of ginsenosides in the treatment of cardiovascular disease have attracted much attention and been the subject of numerous publications. Here, we review the current literature on the myriad pharmacological functions and the potential benefits of ginseng in this area. In vitro investigations using cell cultures and in vivo animal models have indicated ginseng's potential cardiovascular benefits through diverse mechanisms that include antioxidation, modifying vasomotor function, reducing platelet adhesion, influencing ion channels, altering autonomic neurotransmitters release, and improving lipid profiles. Some 40 ginsenosides have been identified. Each may have different effects in pharmacology and mechanisms due to their different chemical structures. This review also summarizes results of relevant clinical trials regarding the cardiovascular effects of ginseng, particularly in the management of hypertension and improving cardiovascular function.



  1. Kritharides L, Brown A, Brieger D, Ridell T, Zeitz C, Jeremy R, Tonkin A, Walsh W, White H. Overview and determinants of cardiovascular disease in indigenous populations. Heart Lung Circ 2010;19:337-343.
  2. Pratt C. Alternative prevention and treatment of cardiovascular disease, part 2. Prim Care 2010;37:339-366.
  3. Ulrich S, Hingorani AD, Martin J, Vallance P. Lifetime risk of developing coronary heart disease. Lancet 1999;353:925.
  4. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, Keil U. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000;355:688-700.
  5. Toth PP. Making a case for quantitative assessment of cardiovascular risk. J Clin Lipidol 2007;1:234-241.
  6. Libby P. What have we learned about the biology of atherosclerosis? The role of infl ammation. Am J Cardiol 2001;88(7B):3J-6J.
  7. Libby P. Act local, act global: infl ammation and the multiplicity of "vulnerable" coronary plaques. J Am Coll Cardiol 2005;45:1600-1602.
  8. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993;171:223-229.
  9. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005;25:2255-2264.
  10. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116:1832-1844.
  11. Schechter CB. Longevity and cardiovascular disease: context and overview. Arch Intern Med 2007;167:428-429.
  12. Boudina S, Laclau MN, Tariosse L, Daret D, Gouverneur G, Bonoron-Adele S, Saks VA, Dos Santos P. Alteration of mitochondrial function in a model of chronic ischemia in vivo in rat heart. Am J Physiol Heart Circ Physiol 2002;282:H821-H831.
  13. Shibata S, Fujita M, Itokawa H, Tanaka O, Ishii T. Studies on the constituents of Japanese and Chinese crude drugs. XI. Panaxadiol, a sapogenin of ginseng roots. Chem Pharm Bull (Tokyo) 1963;11:759-761.
  14. Shibata S, Tanaka O, Soma K, Ando T, Iida Y, Nakamura H. Studies on saponins and sapogenins of ginseng. The structure of panaxatriol. Tetrahedron Lett 1965;42:207-213.
  15. Gillis CN. Panax ginseng pharmacology: a nitric oxide link? Biochem Pharmacol 1997;54:1-8.
  16. Buettner C, Yeh GY, Phillips RS, Mittleman MA, Kaptchuk TJ. Systematic review of the effects of ginseng on cardiovascular risk factors. Ann Pharmacother 2006;40:83-95.
  17. Hofseth LJ, Wargovich MJ. Inflammation, cancer, and targets of ginseng. J Nutr 2007;137(1 Suppl):183S-185S.
  18. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685-1693.
  19. Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, Chen CJ. Molecular mechanisms and clinical applications of ginseng root for cardiovascular disease. Med Sci Monit 2004;10:RA187- RA192.
  20. Cheng Y, Shen LH, Zhang JT. Anti-amnestic and anti-aging effects of ginsenoside $Rg_1$ and $Rb_1$ and its mechanism of action. Acta Pharmacol Sin 2005;26:143-149.
  21. Fuzzati N. Analysis methods of ginsenosides. J Chromatogr B Analyt Technol Biomed Life Sci 2004;812:119-133.
  22. Nah SY, Kim DH, Rhim H. Ginsenosides: are any of them candidates for drugs acting on the central nervous system? CNS Drug Rev 2007;13:381-404.
  23. Brekhman II, Dardymov IV. New substances of plant origin which increase nonspecific resistance. Annu Rev Pharmacol 1969;9:419-30.
  24. Bittles AH, Fulder SJ, Grant EC, Nicholls MR. The effect of ginseng on lifespan and stress responses in mice. Gerontology 1979;25:125-131.
  25. Zhou DH. Preventive geriatrics: an overview from traditional Chinese medicine. Am J Chin Med 1982;10:32-39.
  26. Brekhman II. Panax ginseng. Leningrad: Gosudaarst Isdat et Med Lit, 1957.
  27. Jiang QS, Huang XN, Dai ZK, Yang GZ, Zhou QX, Shi JS, Wu Q. Inhibitory effect of ginsenoside Rb1 on cardiac hypertrophy induced by monocrotaline in rat. J Ethnopharmacol 2007;111:567-572.
  28. Cai BX, Li XY, Chen JH, Tang YB, Wang GL, Zhou JG, Qui QY, Guan YY. Ginsenoside-Rd, a new voltage-independent Ca2+ entry blocker, reverses basilar hypertrophic remodeling in stroke-prone renovascular hypertensive rats. Eur J Pharmacol 2009;606:142-149.
  29. Chen RJ, Chung TY, Li FY, Lin NH, Tzen JT. Effect of sugar positions in ginsenosides and their inhibitory potency on Na+/K+-ATPase activity. Acta Pharmacol Sin 2009;30:61-69.
  30. Choi SH, Lee JH, Pyo MK, Lee BH, Shin TJ, Hwang SH, Kim BR, Lee SM, Oh JW, Kim HC et al. Mutations Leu427, Asn428, and Leu431 residues within transmembrane domain-I-segment 6 attenuate ginsenoside-mediated L-type Ca(2+) channel current inhibitions. Biol Pharm Bull 2009;32:1224-1230.
  31. Jeon BH, Kim CS, Park KS, Lee JW, Park JB, Kim KJ, Kim SH, Chang SJ, Nam KY. Effect of Korea red ginseng on the blood pressure in conscious hypertensive rats. Gen Pharmacol 2000;35:135-141.
  32. Kang SY, Schini-Kerth VB, Kim ND. Ginsenosides of the protopanaxatriol group cause endothelium-dependent relaxation in the rat aorta. Life Sci 1995;56:1577-1586.
  33. Vuksan V, Stavro M, Woo M, Leiter LA, Sung MK, Sievenpiper JL. Korean red ginseng (Panax ginseng) can lower blood pressure in individuals with hypertension: a randomized controlled trial. Proceedings of the 9th International Ginseng Symposium; 2006 Sep 25-28; Geumsan, Korea. Seoul: Korean Society of Ginseng, 2006.
  34. Kim ND, Kang SY, Schini VB. Ginsenosides evoke endothelium- dependent vascular relaxation in rat aorta. Gen Pharmacol 1994;25:1071-1077.
  35. Baek EB, Yoo HY, Park SJ, Chung YS, Hong EK, Kim SJ. Inhibition of arterial myogenic responses by a mixed aqueous extract of salvia miltiorrhiza and Panax notoginseng (PASEL) showing antihypertensive effects. Korean J Physiol Pharmacol 2009;13:287-293.
  36. Wagner HN, Liu X. The international textbook of cardiology. New York: Pergamon Press, 1987.
  37. Liu L, Shi R, Shi Q, Cheng Y, Huo Y. Protective effect of saponins from Panax notoginseng against doxorubicininduced cardiotoxicity in mice. Planta Med 2008;74:203-209.
  38. Qin N, Gong QH, Wei LW, Wu Q, Huang XN. Total ginsenosides inhibit the right ventricular hypertrophy induced by monocrotaline in rats. Biol Pharm Bull 2008;31:1530-1535.
  39. Deng J, Wang YW, Chen WM, Wu Q, Huang XN. Role of nitric oxide in ginsenoside Rg(1)-induced protection against left ventricular hypertrophy produced by abdominal aorta coarctation in rats. Biol Pharm Bull 2010; 33:631-635.
  40. Wang YG, Zima AV, Ji X, Pabbidi R, Blatter LA, Lipsius SL. Ginsenoside Re suppresses electromechanical alternans in cat and human cardiomyocytes. Am J Physiol Heart Circ Physiol 2008;295:H851-H859.
  41. Wang Z, Li M, Wu WK, Tan HM, Geng DF. Ginsenoside $Rb_1$ preconditioning protects against myocardial infarction after regional ischemia and reperfusion by activation of phosphatidylinositol-3-kinase signal transduction. Cardiovasc Drugs Ther 2008;22:443-452.
  42. Deng J, Lv XT, Wu Q, Huang XN. Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: involvement of calcineurin and mitogen-activated protein kinase signalings. Eur J Pharmacol 2009;608:42-47.
  43. Wang YL, Wang CY, Zhang BJ, Zhang ZZ. Shenfu injection suppresses apoptosis by regulation of Bcl-2 and caspase-3 during hypoxia/reoxygenation in neonatal rat cardiomyocytes in vitro. Mol Biol Rep 2009;36:365-370.
  44. Yook T, Yu J, Lee H, Song B, Kim L, Roh J, Shin J, Lim S. Comparing the effects of distilled rehmannia glutinosa, wild ginseng and astragali radix pharmacopuncture with heart rate variability (HRV): a randomized, sham-controlled and double-blind clinical trial. J Acupunct Meridian Stud 2009;2:239-247.
  45. Zhu D, Wu L, Li CR, Wang XW, Ma YJ, Zhong ZY, Zhao HB, Cui J, Xun SF, Huang XL et al. Ginsenoside $Rg_1$ protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis. J Cell Biochem 2009;108:117-124.
  46. Kim TH, Lee SM. The effects of ginseng total saponin, panaxadiol and panaxatriol on ischemia/reperfusion injury in isolated rat heart. Food Chem Toxicol 2010;48:1516-1520.
  47. Wu Y, Xia ZY, Dou J, Zhang L, Xu JJ, Zhao B, Lei S, Liu HM. Protective effect of ginsenoside $Rb_1$ against myocardial ischemia/reperfusion injury in streptozotocin-induced diabetic rats. Mol Biol Rep 2011;38:4327-4335.
  48. Bodiga S, Wang W, Oudit GY. Use of ginseng to reduce post-myocardial adverse myocardial remodeling: applying scientific principles to the use of herbal therapies. J Mol Med (Berl) 2011;89:317-320.
  49. Guo J, Gan XT, Haist JV, Rajapurohitam V, Zeidan A, Faruq NS, Karmazyn M. Ginseng inhibits cardiomyocyte hypertrophy and heart failure via NHE-1 inhibition and attenuation of calcineurin activation. Circ Heart Fail 2011;4:79-88.
  50. Tsutsumi YM, Tsutsumi R, Mawatari K, Nakaya Y, Kinoshita M, Tanaka K, Oshita S. Compound K, a metabolite of ginsenosides, induces cardiac protection mediated nitric oxide via Akt/PI3K pathway. Life Sci 2011;88:725-729.
  51. Zhou H, Hou SZ, Luo P, Zeng B, Wang JR, Wong YF, Jiang ZH, Liu L. Ginseng protects rodent hearts from acute myocardial ischemia-reperfusion injury through GR/ER-activated RISK pathway in an endothelial NOSdependent mechanism. J Ethnopharmacol 2011;135:287-298.
  52. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386.
  53. Schouten O, Poldermans D. Cardiac risk in non-cardiac surgery. Br J Surg 2007;94:1185-1186.
  54. He F, Guo R, Wu SL, Sun M, Li M. Protective effects of ginsenoside $Rb_1$ on human umbilical vein endothelial cells in vitro. J Cardiovasc Pharmacol 2007;50:314-320.
  55. Kim YM, Namkoong S, Yun YG, Hong HD, Lee YC, Ha KS, Lee H, Kwon HJ, Kwon YG, Kim YM. Water extract of Korean red ginseng stimulates angiogenesis by activating the PI3K/Akt-dependent ERK1/2 and eNOS pathways in human umbilical vein endothelial cells. Biol Pharm Bull 2007;30:1674-1679.
  56. Leung KW, Yung KK, Mak NK, Yue PY, Luo HB, Cheng YK, Fan TP, Yeung HW, Ng TB, Wong RN. Angiomodulatory and neurological effects of ginsenosides. Curr Med Chem 2007;14:1371-1380.
  57. Nakaya Y, Mawatari K, Takahashi A, Harada N, Hata A, Yasui S. The phytoestrogen ginsensoside Re activates potassium channels of vascular smooth muscle cells through PI3K/Akt and nitric oxide pathways. J Med Invest 2007;54:381-384.
  58. Leung KW, Leung FP, Huang Y, Mak NK, Wong RN. Non-genomic effects of ginsenoside-Re in endothelial cells via glucocorticoid receptor. FEBS Lett 2007;581: 2423-2428.
  59. Papapetropoulos A. A ginseng-derived oestrogen receptor beta (ERbeta) agonist, Rb1 ginsenoside, attenuates capillary morphogenesis. Br J Pharmacol 2007;152:172-174.
  60. Yu J, Eto M, Akishita M, Kaneko A, Ouchi Y, Okabe T. Signaling pathway of nitric oxide production induced by ginsenoside $Rb_1$ in human aortic endothelial cells: a possible involvement of androgen receptor. Biochem Biophys Res Commun 2007;353:764-769.
  61. Yu LC, Chen SC, Chang WC, Huang YC, Lin KM, Lai PH, Sung HW. Stability of angiogenic agents, ginsenoside $Rg_1$ and Re, isolated from Panax ginseng: in vitro and in vivo studies. Int J Pharm 2007;328:168-176.
  62. Lei Y, Gao Q, Chen KJ. Effects of extracts from Panax notoginseng and Panax ginseng fruit on vascular endothelial cell proliferation and migration in vitro. Chin J Integr Med 2008;14:37-41.
  63. Lin KM, Hsu CH, Rajasekaran S. Angiogenic evaluation of ginsenoside Rg1 from Panax ginseng in fluorescent transgenic mice. Vascul Pharmacol 2008;49:37-43.
  64. Chan LS, Yue PY, Mak NK, Wong RN. Role of microRNA- 214 in ginsenoside-Rg1-induced angiogenesis. Eur J Pharm Sci 2009;38:370-377.
  65. Hong SJ, Wan JB, Zhang Y, Hu G, Lin HC, Seto SW, Kwan YW, Lin ZX, Wang YT, Lee SM. Angiogenic effect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafi sh in vivo. Phytother Res 2009;23:677-686.
  66. Wan JB, Lee SM, Wang JD, Wang N, He CW, Wang YT, Kang JX. Panax notoginseng reduces atherosclerotic lesions in ApoE-deficient mice and inhibits TNF-alphainduced endothelial adhesion molecule expression and monocyte adhesion. J Agric Food Chem 2009;57:6692- 6697.
  67. Hien TT, Kim ND, Pokharel YR, Oh SJ, Lee MY, Kang KW. Ginsenoside $Rg_3$ increases nitric oxide production via increases in phosphorylation and expression of endothelial nitric oxide synthase: essential roles of estrogen receptor-dependent PI3-kinase and AMP-activated protein kinase. Toxicol Appl Pharmacol 2010;246:171-183.
  68. Jeong A, Lee HJ, Jeong SJ, Lee HJ, Lee EO, Bae H, Kim SH. Compound K inhibits basic fi broblast growth factorinduced angiogenesis via regulation of p38 mitogen activated protein kinase and AKT in human umbilical vein endothelial cells. Biol Pharm Bull 2010;33:945-950.
  69. Cheung LW, Leung KW, Wong CK, Wong RN, Wong AS. Ginsenoside-$Rg_1$ induces angiogenesis via non-genomic crosstalk of glucocorticoid receptor and fi broblast growth factor receptor-1. Cardiovasc Res 2011;89:419-425.
  70. He W, Wu WK, Wu YL, Yang XH, Lin QX, Yu WH. Ginsenoside-$Rg_1$ mediates microenvironment-dependent endothelial differentiation of human mesenchymal stem cells in vitro. J Asian Nat Prod Res 2011;13:1-11.
  71. Xu Z, Lan T, Wu W, Wu Y. The effects of ginsenoside $Rb_1$ on endothelial damage and ghrelin expression induced by hyperhomocysteine. J Vasc Surg 2011;53:156-164.
  72. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989;3:2007-2018.
  73. Ignarro LJ. Biological actions and properties of endothelium- derived nitric oxide formed and released from artery and vein. Circ Res 1989;65:1-21.
  74. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
  75. Leung KW, Cheng YK, Mak NK, Chan KK, Fan TP, Wong RN. Signaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells. FEBS Lett 2006;580:3211-3216.
  76. Kang YJ, Sohn JT, Chang KC. Relaxation of canine corporal smooth muscle relaxation by ginsenoside saponin Rg3 is independent from eNOS activation. Life Sci 2005;77:74-84.
  77. Jovanovski E, Jenkins A, Dias AG, Peeva V, Sievenpiper J, Arnason JT, Rahelic D, Josse RG, Vuksan V. Effects of Korean red ginseng (Panax ginseng C.A. Mayer) and its isolated ginsenosides and polysaccharides on arterial stiffness in healthy individuals. Am J Hypertens 2010;23:469-472.
  78. Lee JY, Lim KM, Kim SY, Bae ON, Noh JY, Chung SM, Kim K, Shin YS, Lee MY, Chung JH. Vascular smooth muscle dysfunction and remodeling induced by ginsenoside $Rg_3$, a bioactive component of ginseng. Toxicol Sci 2010;117:505-514.
  79. Wang T, Yu XF, Qu SC, Xu HL, Sui DY. Ginsenoside $Rb_3$ inhibits angiotensin II-induced vascular smooth muscle cells proliferation. Basic Clin Pharmacol Toxicol 2010;107:685-689.
  80. Wu L, Zhang W, Tang YH, Li H, Chen BY, Zhang GM, Deng CQ. Effect of total saponins of "Panax notoginseng root" on aortic intimal hyperplasia and the expressions of cell cycle protein and extracellular matrix in rats. Phytomedicine 2010;17:233-240.
  81. Rhee MY, Kim YS, Bae JH, Nah DY, Kim YK, Lee MM, Kim HY. Effect of Korean red ginseng on arterial stiffness in subjects with hypertension. J Altern Complement Med 2011;17:45-49.
  82. Tamura Y. Effects of Korean red ginseng on eicosanoid biosynthesis in platelets and vascular smooth muscle cells. Proceedings of the 6th Internationa1 Ginseng Symposium; 1993 Sep 6-9; Seoul, Korea. Daejeon: Korea Ginseng & Tobacco Research Institute, 1993.
  83. Harima S, Matsuda H, Kubo M. Study of various rhubarbs regarding the cathartic effect and endotoxin-induced disseminated intravascular coagulation. Biol Pharm Bull 1994;17:1522-1525.
  84. Jin YR, Yu JY, Lee JJ, You SH, Chung JH, Noh JY, Im JH, Han XH, Kim TJ, Shin KS et al. Antithrombotic and antiplatelet activities of Korean red ginseng extract. Basic Clin Pharmacol Toxicol 2007;100:170-175.
  85. Lee WM, Kim SD, Park MH, Cho JY, Park HJ, Seo GS, Rhee MH. Inhibitory mechanisms of dihydroginsenoside Rg3 in platelet aggregation: critical roles of ERK2 and cAMP. J Pharm Pharmacol 2008;60:1531-1536.
  86. Li GX, Liu ZQ. The protective effects of ginsenosides on human erythrocytes against hemin-induced hemolysis. Food Chem Toxicol 2008;46:886-892.
  87. Wang J, Huang ZG, Cao H, Wang YT, Hui P, Hoo C, Li SP. Screening of anti-platelet aggregation agents from Panax notoginseng using human platelet extraction and HPLC-DAD-ESI-MS/MS. J Sep Sci 2008;31:1173-1180.
  88. Yang JY, Sun K, Wang CS, Guo J, Xue X, Liu YY, Zheng J, Fan JY, Liao FL, Han JY. Improving effect of posttreatment with Panax notoginseng saponins on lipopolysaccharide- induced microcirculatory disturbance in rat mesentery. Clin Hemorheol Microcirc 2008;40:119-131.
  89. Lau AJ, Toh DF, Chua TK, Pang YK, Woo SO, Koh HL. Antiplatelet and anticoagulant effects of Panax notoginseng: comparison of raw and steamed Panax notoginseng with Panax ginseng and Panax quinquefolium. J Ethnopharmacol 2009;125:380-386.
  90. Lee JG, Lee YY, Kim SY, Pyo JS, Yun-Choi HS, Park JH. Platelet antiaggregating activity of ginsenosides isolated from processed ginseng. Pharmazie 2009;64:602-604.
  91. Lee JG, Lee YY, Wu B, Kim SY, Lee YJ, Yun-Choi HS, Park JH. Inhibitory activity of ginsenosides isolated from processed ginseng on platelet aggregation. Pharmazie 2010;65:520-522.
  92. Lee YH, Lee BK, Choi YJ, Yoon IK, Chang BC, Gwak HS. Interaction between warfarin and Korean red ginseng in patients with cardiac valve replacement. Int J Cardiol 2010;145:275-276.
  93. Yi XQ, Li T, Wang JR, Wong VK, Luo P, Wong IY, Jiang ZH, Liu L, Zhou H. Total ginsenosides increase coronary perfusion fl ow in isolated rat hearts through activation of PI3K/Akt-eNOS signaling. Phytomedicine 2010;17:1006-1015.
  94. Ahn CM, Hong SJ, Choi SC, Park JH, Kim JS, Lim DS. Red ginseng extract improves coronary fl ow reserve and increases absolute numbers of various circulating angiogenic cells in patients with first ST-segment elevation acute myocardial infarction. Phytother Res 2011;25:239-249.
  95. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
  96. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA et al. Activation of the nuclear receptor LXR by oxysterols defi nes a new hormone response pathway. J Biol Chem 1997;272:3137-3140.
  97. Karu N, Reifen R, Kerem Z. Weight gain reduction in mice fed Panax ginseng saponin, a pancreatic lipase inhibitor. J Agric Food Chem 2007;55:2824-2828.
  98. Trinh HT, Han SJ, Kim SW, Lee YC, Kim DH. Bifidus fermentation increases hypolipidemic and hypoglycemic effects of red ginseng. J Microbiol Biotechnol 2007;17:1127-1133.
  99. Hwang SY, Son DJ, Kim IW, Kim DM, Sohn SH, Lee JJ, Kim SK. Korean red ginseng attenuates hypercholesterolemia- enhanced platelet aggregation through suppression of diacylglycerol liberation in high-cholesterol-diet-fed rabbits. Phytother Res 2008;22:778-783.
  100. Zhang YG, Zhang HG, Zhang GY, Fan JS, Li XH, Liu YH, Li SH, Lian XM, Tang Z. Panax notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profi le and an anti-infl ammatory action. Clin Exp Pharmacol Physiol 2008;35:1238-1244.
  101. Liu G, Wang B, Zhang J, Jiang H, Liu F. Total panax notoginsenosides prevent atherosclerosis in apolipoprotein E-knockout mice: role of downregulation of CD40 and MMP-9 expression. J Ethnopharmacol 2009;126:350-354.
  102. Jia Y, Li ZY, Zhang HG, Li HB, Liu Y, Li XH. Panax notoginseng saponins decrease cholesterol ester via upregulating ATP-binding cassette transporter A1 in foam cells. J Ethnopharmacol 2010;132:297-302.
  103. Kwak YS, Kyung JS, Kim JS, Cho JY, Rhee MH. Anti-hyperlipidemic effects of red ginseng acidic polysaccharide from Korean red ginseng. Biol Pharm Bull 2010;33:468-472.
  104. Liu Y, Zhang HG, Jia Y, Li XH. Panax notoginseng saponins attenuate atherogenesis accelerated by zymosan in rabbits. Biol Pharm Bull 2010;33:1324-1330.
  105. Xia W, Sun C, Zhao Y, Wu L. Hypolipidemic and antioxidant activities of sanchi (radix notoginseng) in rats fed with a high fat diet. Phytomedicine 2011;18:516-520.
  106. Li J, Xie ZZ, Tang YB, Zhou JG, Guan YY. Ginsenoside-Rd, a purifi ed component from Panax notoginseng saponins, prevents atherosclerosis in apoE knockout mice. Eur J Pharmacol 2011;652:104-110.
  107. Bolli R. Superoxide dismutase 10 years later: a drug in search of a use. J Am Coll Cardiol 1991;18:231-233.
  108. Gross GJ, Farber NE, Hardman HF, Warltier DC. Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs. Am J Physiol 1986;250(3 Pt 2):H372- H377.
  109. Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci U S A 1987;84:1404-1407.
  110. Xie YW, Shen W, Zhao G, Xu X, Wolin MS, Hintze TH. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure. Circ Res 1996;79:381-387.
  111. Taniguchi M, Wilson C, Hunter CA, Pehowich DJ, Clanachan AS, Lopaschuk GD. Dichloroacetate improves cardiac effi ciency after ischemia independent of changes in mitochondrial proton leak. Am J Physiol Heart Circ Physiol 2001;280:H1762- H1769.
  112. Abdel-Wahhab MA, Ahmed HH. Protective effect of Korean Panax ginseng against chromium VI toxicity and free radicals generation in rats. J Ginseng Res 2004;28:11-17.
  113. Chung YH, Kim KW, Oura H. Effects of ginsenoside $Rb_2$ on the anti-oxidants in senescence-accelerated mice (SAM-R/1). Proceedings of the 6th Internationa1 Ginseng Symposium; 1993 Sep 6-9; Seoul, Korea. Daejeon: Korea Ginseng & Tobacco Research Institute, 1993.
  114. Chang HM; Chinese University of Hong Kong; Chinese Medicinal Research Centre. Advances in Chinese medicinal materials research. Philadelphia: World Scientifi c, 1985.
  115. Kim H, Chen X, Gillis CN. Ginsenosides protect pulmonary vascular endothelium against free radical-induced injury. Biochem Biophys Res Commun 1992;189:670-676.
  116. Kim YK, Guo Q, Packer L. Free radical scavenging activity of red ginseng aqueous extracts. Toxicology 2002;172:149-156.
  117. Samukawa K, Suzuki Y, Ohkubo N, Aoto M, Sakanaka M, Mitsuda N. Protective effect of ginsenosides Rg(2) and Rh(1) on oxidation-induced impairment of erythrocyte membrane properties. Biorheology 2008;45:689-700.
  118. Li XT, Chen R, Jin LM, Chen HY. Regulation on energy metabolism and protection on mitochondria of Panax ginseng polysaccharide. Am J Chin Med 2009;37:1139-1152.
  119. Li J, Ichikawa T, Jin Y, Hofseth LJ, Nagarkatti P, Nagarkatti M, Windust A, Cui T. An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes. J Ethnopharmacol 2010;130:222-230.
  120. Fu Y, Ji LL. Chronic ginseng consumption attenuates age-associated oxidative stress in rats. J Nutr 2003;133:3603-3609.
  121. Chen X. Cardiovascular protection by ginsenosides and their nitric oxide releasing action. Clin Exp Pharmacol Physiol 1996;23:728-732.
  122. Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Ginsenoside $Rb_1$ blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2005;41:861-868.
  123. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defi c Syndr 2007;44:493-499.
  124. Xie JT, Shao ZH, Vanden Hoek TL, Chang WT, Li J, Mehendale S, Wang CZ, Hsu CW, Becker LB, Yin JJ et al. Antioxidant effects of ginsenoside Re in cardiomyocytes. Eur J Pharmacol 2006;532:201-207.
  125. Deng HL, Zhang JT. Anti-lipid peroxilative effect of ginsenoside $Rb_1$ and $Rg_1$. Chin Med J (Engl) 1991;104:395-398.
  126. Lim JH, Wen TC, Matsuda S, Tanaka J, Maeda N, Peng H, Aburaya J, Ishihara K, Sakanaka M. Protection of ischemic hippocampal neurons by ginsenoside $Rb_1$, a main ingredient of ginseng root. Neurosci Res 1997;28:191-200.
  127. Tian J, Fu F, Geng M, Jiang Y, Yang J, Jiang W, Wang C, Liu K. Neuroprotective effect of 20(S)-ginsenoside $Rg_3$ on cerebral ischemia in rats. Neurosci Lett 2005;374:92-97.
  128. Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009;7:293-302.

Cited by

  1. Korean Red Ginseng Induced Cardioprotection against Myocardial Ischemia in Guinea Pig vol.17, pp.4, 2013,
  2. Red-Koji Fermented Red Ginseng Ameliorates High Fat Diet-Induced Metabolic Disorders in Mice vol.5, pp.11, 2013,
  3. Comparative mRNA and microRNA expression profiling of methylglyoxal-exposed human endothelial cells vol.7, pp.2, 2013,
  4. An integrated analysis of microRNA and mRNA expression in salvianolic acid B-treated human umbilical vein endothelial cells vol.9, pp.1, 2013,
  5. Cardioprotective Effect of Rhizomes of Acorus gramineus Against Isoproterenol-Induced Cardiac Damage in Pigs vol.14, pp.2, 2014,
  6. Ginsenoside Rg1 Prevents Cognitive Impairment and Hippocampus Senescence in a Rat Model of D-Galactose-Induced Aging vol.9, pp.6, 2014,
  7. Renoprotective effect of red ginseng in gentamicin-induced acute kidney injury vol.94, pp.10, 2014,
  8. The Long-Term Consumption of Ginseng Extract Reduces the Susceptibility of Intermediate-Aged Hearts to Acute Ischemia Reperfusion Injury vol.10, pp.12, 2015,
  9. Neuroprotective effects of pretreatment of ginsenoside Rb1 on severe cerebral ischemia-induced injuries in aged mice: Involvement of anti-oxidant signaling vol.17, pp.2, 2017,
  10. Anti-inflammatory potential of saponins derived from cultured wild ginseng roots in lipopolysaccharide-stimulated RAW 264.7 macrophages vol.35, pp.6, 2015,
  11. Recent trends of nano bioactive compounds from ginseng for its possible preventive role in chronic disease models vol.5, pp.119, 2015,
  12. in rats: in vitro and in vivo insights from quantitative ultra-performance liquid chromatography-mass spectrometry analysis vol.7, pp.15, 2015,
  13. New Potential Pharmacological Functions of Chinese Herbal Medicines via Regulation of Autophagy vol.21, pp.3, 2016,
  14. Antioxidant and hepatoprotective effects of fermented red ginseng against high fat diet-induced hyperlipidemia in rats vol.32, pp.4, 2016,
  15. TCM, brain function and drug space vol.33, pp.1, 2016,
  16. Anti-hypertensive Herbs and their Mechanisms of Action: Part I vol.6, pp.1663-9812, 2015,
  17. Chinese Herbal Medicine on Cardiovascular Diseases and the Mechanisms of Action vol.7, pp.1663-9812, 2016,
  18. Herbs Used for the Treatment of Hypertension and their Mechanism of Action vol.19, pp.9, 2017,
  19. Study on Transformation of Ginsenosides in Different Methods vol.2017, pp.2314-6141, 2017,
  20. Ginsenoside Rg1 improves fertility and reduces ovarian pathological damages in premature ovarian failure model of mice vol.242, pp.7, 2017,
  21. Combination of ginsenoside Rb1 and Rd protects the retina against bright light-induced degeneration vol.7, pp.1, 2017,
  22. TCM-Mesh: The database and analytical system for network pharmacology analysis for TCM preparations vol.7, pp.1, 2017,
  23. Global deregulation of ginseng products may be a safety hazard to warfarin takers: solid evidence of ginseng-warfarin interaction vol.7, pp.1, 2017,
  24. Anti-adipogenic Effects and Mechanisms of Ginsenoside Rg3 in Pre-adipocytes and Obese Mice vol.8, pp.1663-9812, 2017,
  25. Integrated Transcriptomic and Metabolomic Analysis of Five Panax ginseng Cultivars Reveals the Dynamics of Ginsenoside Biosynthesis vol.8, pp.1664-462X, 2017,
  26. Effect of Shen-Fu Injection (参附注射液) on hemodynamics in early volume resuscitation treated septic shock patients pp.1993-0402, 2017,
  27. ) Decreases Isoproterenol-Induced Cardiac Injury via Antioxidant Properties in Porcine vol.17, pp.1, 2014,
  28. using simultaneous UPLC-ESI-MS/MS vol.38, pp.4, 2018,
  29. Ginsenosides: A Potential Neuroprotective Agent vol.2018, pp.2314-6141, 2018,
  30. Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes vol.9, pp.1663-9812, 2018,
  31. Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment vol.10, pp.1663-9812, 2019,
  32. B in HUVECs following LPS Stimulation vol.2019, pp.1942-0994, 2019,
  33. Effect of Korean red ginseng extract on liver damage induced by shortterm and long-term ethanol treatment in rats vol.37, pp.2, 2013,
  34. Ginsenoside-Re ameliorates ischemia and reperfusion injury in the heart: a hemodynamics approach vol.37, pp.3, 2012,
  35. Bidirectional regulation of angiogenesis and miR-18a expression by PNS in the mouse model of tumor complicated by myocardial ischemia vol.14, pp.None, 2012,
  36. Protective effects of ginseng extracts and common anti-aggregant drugs on ischaemia–reperfusion injury vol.26, pp.6, 2012,
  37. Ginsenoside Rg3 Improves Cardiac Function after Myocardial Ischemia/Reperfusion via Attenuating Apoptosis and Inflammation vol.2016, pp.None, 2012,
  38. Rg3-enriched Korean Red Ginseng enhances blood pressure stability in spontaneously hypertensive rats vol.5, pp.3, 2016,
  39. Biological characteristics of Paenibacillus polymyxa GBR-1 involved in root rot of stored Korean ginseng vol.40, pp.4, 2012,
  40. Comparative analysis of chloroplast DNA sequences of Codonopsis lanceolata and Platycodon grandiflorus and application in development of molecular markers vol.60, pp.1, 2012,
  41. Herbal products containing Hibiscus sabdariffa L., Crataegus spp., and Panax spp.: Labeling and safety concerns vol.100, pp.1, 2012,
  42. Role of ginsenosides in reactive oxygen species-mediated anticancer therapy vol.9, pp.2, 2018,
  43. Electrodeposition of Ginseng/Polyaniline Encapsulated Poly(lactic-co-glycolic Acid) Microcapsule Coating on Stainless Steel 316L at Different Deposition Parameters vol.67, pp.5, 2012,
  44. American Ginseng (Panax quinquefolium L.) as a Source of Bioactive Phytochemicals with Pro-Health Properties vol.11, pp.5, 2012,
  45. Neuroprotective Effects of Red Ginseng Saponins in Scopolamine-Treated Rats and Activity Screening Based on Pharmacokinetics vol.24, pp.11, 2012,
  46. Microbial Metabolites Determine Host Health and the Status of Some Diseases vol.20, pp.21, 2012,
  47. Ginsenoside Rb2 Ameliorates LPS-Induced Inflammation and ER Stress in HUVECs and THP-1 Cells via the AMPK-Mediated Pathway vol.48, pp.4, 2012,
  48. Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems vol.27, pp.4, 2020,
  49. Antihypertensive Effects of Rg3-Enriched Korean Vitamin Ginseng in Spontaneously Hypertensive Rats vol.15, pp.1, 2012,
  50. Preventive treatment with ginsenoside Rb1 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats and involves store-operated calcium entry inhibition vol.58, pp.1, 2012,
  51. Red Ginseng Inhibits Tau Aggregation and Promotes Tau Dissociation In Vitro vol.2020, pp.None, 2020,
  52. Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety vol.11, pp.None, 2012,
  53. Notoginsenoside R1–Induced Neuronal Repair in Models of Alzheimer Disease Is Associated With an Alteration in Neuronal Hyperexcitability, Which Is Regulated by Nav vol.14, pp.None, 2012,
  54. Potential benefits of garlic and other dietary supplements for the management of hypertension vol.19, pp.2, 2012,
  55. Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton’s Tyrosine Kinase Inhibitor vol.21, pp.9, 2020,
  56. Characteristics of Panax ginseng Cultivars in Korea and China vol.25, pp.11, 2012,
  57. Myristoleic acid produced by enterococci reduces obesity through brown adipose tissue activation vol.69, pp.7, 2020,
  58. Different absorption and metabolism of ginsenosides after the administration of total ginsenosides and decoction of Panax ginseng vol.34, pp.13, 2020,
  59. Pseudo-ginsengenin DQ ameliorated aconitine-induced arrhythmias by influencing Ca2+ and K+ currents in ventricular myocytes vol.10, pp.43, 2020,
  60. Biochemical and molecular characterization of enhanced growth of Panax ginseng C. A. Meyer treated with atmospheric pressure plasma vol.53, pp.49, 2020,
  61. An LCI‐like protein APC2 protects ginseng root from Fusarium solani infection vol.130, pp.1, 2012,
  62. Ginsenoside Rc Ameliorates Endothelial Insulin Resistance via Upregulation of Angiotensin-Converting Enzyme 2 vol.12, pp.None, 2012,
  63. Panax Ginseng C.A.Mey. as Medicine: The Potential Use of Panax Ginseng C.A.Mey. as a Remedy for Kidney Protection from a Pharmacological Perspective vol.12, pp.None, 2012,
  64. Recent progress in polysaccharides from Panax ginseng C. A. Meyer vol.12, pp.2, 2012,
  65. Identification of Specific Glycosyltransferases Involved in Flavonol Glucoside Biosynthesis in Ginseng Using Integrative Metabolite Profiles, DIA Proteomics, and Phylogenetic Analysis vol.69, pp.5, 2012,
  66. Effect of Korean Red Ginseng on metabolic syndrome vol.45, pp.3, 2012,
  67. Herbal Extract from Codonopsis pilosula (Franch.) Nannf. Enhances Cardiogenic Differentiation and Improves the Function of Infarcted Rat Hearts vol.11, pp.5, 2012,
  68. Inhibition of Angiotensin-I Converting Enzyme by Ginsenosides: Structure-Activity Relationships and Inhibitory Mechanism vol.69, pp.21, 2012,
  69. Inhibition of Angiotensin-I Converting Enzyme by Ginsenosides: Structure-Activity Relationships and Inhibitory Mechanism vol.69, pp.21, 2012,
  70. Production of Minor Ginsenosides C-K and C-Y from Naturally Occurring Major Ginsenosides Using Crude β-Glucosidase Preparation from Submerged Culture of Fomitella fraxinea vol.26, pp.16, 2021,
  71. Medicinal Plants in the Treatment of Hypertension: A Review vol.11, pp.4, 2021,
  72. Use of Acyl-Homoserine Lactones Leads to Improved Growth of Ginseng Seedlings and Shifts in Soil Microbiome Structure vol.11, pp.11, 2012,
  73. Systematic investigation for the mechanisms and the substance basis of Yang–Xin–Ding–Ji capsule based on the metabolite profile and network pharmacology vol.35, pp.12, 2012,